|4Oct 2, 4:39 PM ET

Fitzgerald Thomas A 4

4 · Transcode Therapeutics, Inc. · Filed Oct 2, 2023

Insider Transaction Report

Form 4
Period: 2023-09-28
Fitzgerald Thomas A
DirectorVP, Chief Financial Officer
Transactions
  • Purchase

    Common Stock

    2023-09-28$0.51/sh+49,350$25,16956,318 total
Footnotes (2)
  • [F1]Represents shares acquired pursuant to an underwritten public offering of common stock by the Issuer.
  • [F2]Reported amount reflects a 1-for-20 reverse stock split of the Issuer's common stock, which became effective as of May 22, 2023.

Documents

1 file
  • 4
    tm2327413d2_4seq1.xmlPrimary

    OWNERSHIP DOCUMENT